Federal Circuit Finds Written Description Support for Narrow Claim Range via Disclosure of Broader Ranges, Vacates PTAB Decision

March 15, 2024

Reading Time : 3 min

The Federal Circuit recently vacated a PTAB decision that claims of an “e-cigarette” patent were unpatentable for lack of written description under 35 U.S.C. § 112. The question on appeal was whether a claimed range was adequately supported by the disclosure of broader ranges. In this case, the answer was “yes.”

The patent-at-issue—RAI Strategic Holdings, Inc.’s U.S. Patent No. 10,492,542—generally relates to “electrically powered smoking articles,” or “e-cigarettes.”  In 2020, Philip Morris Products S.A. sought post grant review of the ’542 Patent, asserting (among other grounds) that dependent claims 10 and 27 were invalid for lack of written description. Those claims recited, in relevant part, a “heating member” with “a length of about 75% to about 85% of a length of [a] disposable aerosol forming substance.”

At the PTAB, Philip Morris argued that the claimed range of “about 75% to about 85%” lacked written description support because the specification disclosed only ranges of 75–125%, 80–120%, 85–115% and 90–110%. According to Philip Morris and its expert, those disclosures did not support the claimed range because (1) they were all “substantially narrower” than the claimed range, (2) none of them recited “an upper limit of 85%” as claimed and (3) they all “centered on” 100%, unlike the claim, which centered on 80%. RAI countered that the disclosed ranges of 75–125% and 85–115% together supported the claim because they expressly include “both ends of the claim range,” i.e., 75% and 85%. Nonetheless, the PTAB agreed with Philip Morris and found the claims unpatentable. RAI appealed.

On appeal, the Federal Circuit vacated the PTAB’s decision, concluding that the facts more closely aligned with decisions finding written description support for a claim range. In re Wertheim, for example, held that the disclosure of coffee grounds with “25% to 60%” solid coffee extract supported a claim range of “between 35% and 60%.” 541 F.2d 257 (C.C.P.A. 1976). Importantly, the Wertheim court found no evidence that the “broad described range pertain[ed] to a different invention than the narrower (and subsumed) claimed range.” 

Here, the Federal Circuit likewise saw no evidence—including from Philip Morris’s expert—that the disclosed ranges were “different inventions” than the claimed range. That is, “nothing in the specification indicate[d] that changing the length of the heating member changes the invention, whether as to operability, effectiveness, or any other parameter.” Although the specification did not disclose the claimed range, it did expressly disclose both endpoints of the claimed range. Moreover, the “predictability of electro-mechanical inventions” such as e-cigarettes further supported the Federal Circuit’s ruling, as predictable art requires “a lower level of detail” to satisfy written description than unpredictable art.

The Court also grappled with cases that found a lack of written description on somewhat similar facts, most notably Indivior UK Ltd. v. Dr. Reddy’s Laboratories S.A., 18 F. 4th 1323 (Fed. Cir. 2021). The Indivior claims recited a therapeutic film comprising “about 48.2 wt % to about 58.6 wt %” polymers. The specification, meanwhile, disclosed a table with a 48.2 wt % polymer and a 58.6 wt % polymer—the endpoints of the claimed range. However, unlike the present case, in Indivior, there was a “lack of persuasive evidence that a skilled artisan would have understood the application as disclosing an invention with the range between these endpoints.” The Indivior patent also differed in that it involved an unpredictable art and the specification made “inconsistent statements regarding the desired amount of polymer.”

Finally, in coming to its conclusion, the Federal Circuit repeatedly emphasized that written description is assessed on a case-by-case basis and that “broadly articulated rules are particularly inappropriate in this area.” Instead, one must consider the technology at issue, the predictability of the art, the complexity of the claim limitation and the knowledge gained by a person skilled in the art reading the specification. Thus, while the Court relied on prior cases for support and guidance, its ruling was ultimately “based on the unique facts of this case.”

Practice Tip: Although claims directed to ranges that are not explicitly disclosed in the specification may be susceptible to written description attacks, particularly in arts regarded as unpredictable, the RAI case shows that such claims may be adequately supported if the disclosed and claim ranges are not shown to be “different inventions.” Parties asserting and defending against such attacks should focus arguments on the specific facts of the case and, if possible, provide expert testimony that addresses how exactly the claim range is (or is not) a different invention from the ranges disclosed in the patent.

RAI Strategic Holdings, Inc. v. Philip Morris Products S.A., No. 22-1862 (Fed. Cir. Feb. 9, 2024)

Share This Insight

Previous Entries

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

IP Newsflash

January 17, 2025

The District of Arizona recently held that a plaintiff’s failure to mark patented products during the time period that marking was required barred it from recovering all pre-notice damages, including for a period of time when there was no obligation to mark.

...

Read More

IP Newsflash

January 16, 2025

The Unified Patent Court (UPC) aims to provide expeditious decisions for its litigants. That means that there is a higher bar for obtaining extensions of time. As exemplified in BMW v. ITCiCo, the UPC’s reluctance to grant extensions can have serious consequences, including revocation of the patent.

...

Read More

IP Newsflash

January 15, 2025

The Patent Trial and Appeal Board granted institution of inter partes review of a patent directed to delivery of targeted television advertisements. The board rejected patent owner’s argument that a lack of particularity as to the asserted grounds justified denial under 35 U.S.C. § 312(a), holding that “simply including a significant amount of testimony and a number of supporting references is not, by itself, a reason to find that the particularity requirement is not met.”

...

Read More

IP Newsflash

December 2, 2024

The Patent Trial and Appeal Board determined that a reference could be used as prior art because patent owner failed to provide sufficient evidence that the prior art’s disclosure was invented by all four named inventors, and thus the same “inventive entity,” as the challenged claims.

...

Read More

IP Newsflash

December 2, 2024

The Patent Trial and Appeal Board rejected a patent owner’s assertion that petitioner should have named a third party, which was a defendant in a related district court patent infringement litigation and a party to a joint defense agreement (JDA) with petitioner, as a real party-in-interest (RPI). Had the board ruled otherwise and found the third party to be an RPI, the petition would have been time-barred under 35 U.S.C. § 315(b).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.